The 2021 Biopharmaceutical Innovation Technology Conference (BPIT 2021) will be held at the Crowne Plaza Shanghai Jiangong Pujiang from April 9th to 10th, 2021. Professor Yang Xuanming, Chief Scientist of Shanghai Longyao Biotechnology Co., Ltd., was invited to publish a report entitled "Research Progress of CD20-CART-OX40 in Tumor Killing Persistence" and participated in the research and development driving force of the next generation of CAR-T cells. : Safety, Efficacy and Commercialization" roundtable forum.
Professor Yang Xuanming, Chief Scientist of Longyao Biology, delivered a speech to the guests
Professor Yang Xuanming, Chief Scientist of Longyao Biology, attended the roundtable meeting
In the report, Professor Yang elaborated on the advantages of Longyao's self-developed CD20-CART-OX40 cells in tumor treatment and the unique design of Longyao's independent intellectual property rights of the parallel full-length OX40 costimulatory signal, which led to the participation of There was great interest from conference attendees, and attendees were particularly concerned about the potential of this design to treat solid tumors.
According to earlier news, the registration clinical trial application of Shanghai Longyao Biotechnology Co., Ltd.'s first autologous CAR-T product "LY007 cell injection" has been approved by the State Drug Administration on January 20, 2021. On January 27, 2021, Eastern Time, a team led by Longyao Chief Scientist Professor Yang Xuanming published a research article on CD20-CART-OX40 in Science Translational Medicine.
About Professor Yang Xuanming
Professor Yang Xuanming is a special researcher/tenured associate professor at Shanghai Jiaotong University, a postdoctoral fellow at the Department of Pathology at the University of Chicago, a Ph.D.
The research field focuses on the immunosuppression of the tumor microenvironment, CAR-T and T-cell adoptive tumor therapy. The main recent research directions focus on tumor immunology and tumor immunotherapy. The research results have been published in journals such as Nature Medicine, PNAS, Cancer Cell, Cell Host Microbe, Molecular Therapy and Journal of Immunology. He has applied for a national patent and won the first prize of Beijing Science and Technology Award in 2011.
About LY007 Cell Injection
LY007 cell injection is a chimeric antigen receptor T cell (CAR-T) injection, mainly used for the treatment of relapsed and refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and transformed follicular lymphoma. LY007 cell injection is independently developed by Shanghai Longyao Biotechnology Co., Ltd. and adopts the OX40 costimulatory signal design with independent intellectual property rights. Both preclinical and clinical trials have demonstrated that the design improves the efficacy of the product while ensuring safety. LY007 cell injection is currently the first and only CD20-targeted CAR-T drug approved for clinical application in China.